EUVIMEDEUVIMED entdecken
Multizentrische Studie

Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism

Yugo Yamashita, Hidewo Amano, Takeshi Morimoto, Kazushige Kadota, Reo Hata, Kazuki Matsushita, Kohei Osakada, Arata Sano, Toru Takase, Seiichi Hiramori, Kitae Kim, Maki Oi und 19 weitere

Journal of Thrombosis and Thrombolysis · 2022-01 · 53 (1) · 182-190

DOI: 10.1007/s11239-021-02520-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Thrombolysis, online erschienen am 06.07.2021. Verfasst von Yugo Yamashita und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Hauptthemen laut MEDLINE: Venous Thromboembolism. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Independent clinical research organization, Mitsubishi Tanabe Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolonged anticoagulation therapy is recommended for patients with intermediate-risk for recurrence of venous thromboembolism (VTE). The current study aimed to identify risk factors of VTE recurrence and major bleeding in intermediate-risk patients. The COMMAND VTE Registry is a multicenter registry enrolled consecutive 3027 patients with acute symptomatic VTE among 29 centers in Japan. The current study population consisted of 1703 patients with intermediate-risk for recurrence. The primary outcome measure was recurrent VTE during the entire follow-up period, and the secondary outcome measures were recurrent VTE and major bleeding during anticoagulation therapy. In the multivariable Cox regression model for recurrent VTE incorporating the status of anticoagulation therapy as a time-updated covariate, off-anticoagulation therapy was strongly associated with an increased risk for recurrent VTE (HR 9.42, 95% CI 5.97-14.86). During anticoagulation therapy, the independent risk factor for recurrent VTE was thrombophilia (HR 3.58, 95% CI 1.56-7.50), while the independent risk factors for major bleeding were age ≥ 75 years (HR 2.04, 95% CI 1.36-3.07), men (HR 1.52, 95% CI 1.02-2.27), history of major bleeding (HR 3.48, 95% CI 1.82-6.14) and thrombocytopenia (HR 3.73, 95% CI 2.04-6.37). Among VTE patients with intermediate-risk for recurrence, discontinuation of anticoagulation therapy was a very strong independent risk factor of recurrence during the entire follow-up period. The independent risk factors of recurrent VTE and those of major bleeding during anticoagulation therapy were different: thrombophilia for recurrent VTE, and advanced age, men, history of major bleeding, and thrombocytopenia for major bleeding. CLINICAL TRIAL REGISTRATION: Unique identifier: UMIN000021132. COMMAND VTE Registry: http://www.umin.ac.jp/ctr/index.htm .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismAgedAnticoagulantsHemorrhageHumansMaleRecurrenceRisk Factors

Stichwörter der Autor:innen

BleedingClinical equipoiseIntermediate riskRecurrenceVenous thromboembolism

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Department of Cardiology, Kinki University Hospital, Osaka, Japan.
  • Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan.
  • Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.

Förderung

  • Independent clinical research organization
  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Yamashita, Y., Amano, H., Morimoto, T., Kadota, K., Hata, R., Matsushita, K., Osakada, K., Sano, A., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., Inoko, M., Tada, T., Chen, P. M., Murata, K., …, & COMMAND VTE Registry Investigators (2022). Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 53(1), 182-190. https://doi.org/10.1007/s11239-021-02520-5

Vancouver

Yamashita Y, Amano H, Morimoto T, Kadota K, Hata R, Matsushita K, et al. Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2022;53(1):182-190. doi:10.1007/s11239-021-02520-5

BibTeX
@article{Yamashita2022,
  author = {Yamashita, Yugo and Amano, Hidewo and Morimoto, Takeshi and Kadota, Kazushige and Hata, Reo and Matsushita, Kazuki and Osakada, Kohei and Sano, Arata and Takase, Toru and Hiramori, Seiichi and Kim, Kitae and Oi, Maki and Akao, Masaharu and Kobayashi, Yohei and Toyofuku, Mamoru and Inoko, Moriaki and Tada, Tomohisa and Chen, Po-Min and Murata, Koichiro and Tsuyuki, Yoshiaki and Nishimoto, Yuji and Sasa, Tomoki and Sakamoto, Jiro and Kinoshita, Minako and Togi, Kiyonori and Mabuchi, Hiroshi and Takabayashi, Kensuke and Kato, Takao and Ono, Koh and Kimura, Takeshi and COMMAND VTE Registry Investigators, COMMAND VTE Registry Investigators},
  title = {Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2022},
  volume = {53},
  number = {1},
  pages = {182--190},
  doi = {10.1007/s11239-021-02520-5}
}
Kostenlos starten →